New Kidney Protein Discovery Linked to Phosphate Balance and Vascular Health
Researchers at the University of Colorado Anschutz School of Medicine have identified a kidney protein, TMEM174, that regulates blood phosphate levels and protects blood vessel integrity.
Key Clinical Takeaways:
- TMEM174 helps maintain phosphate homeostasis by destabilizing the NPT2A protein, which otherwise promotes excessive phosphate reabsorption in the kidneys.
- Deficiency in TMEM174 leads to accelerated vascular calcification and reduced life expectancy in animal models, particularly when dietary phosphate intake is high.
- Future therapeutic strategies may focus on targeting TMEM174 to manage hyperphosphatemia, a condition that frequently complicates chronic kidney disease.
The study, published in October 2026 in the journal Scientific Reports, demonstrates that blood vessel stiffening is directly linked to elevated phosphate concentrations. As vessels lose their natural elasticity, the resulting calcification increases the risk of cardiovascular morbidity.
According to the research published at DOI: 10.1038/s41598-026-74353-2, the absence of TMEM174 disrupts the body’s ability to filter waste effectively, causing smooth muscle cells in arterial walls to mimic bone-forming cells.
This process results in the deposition of calcium phosphate crystals within the vessel walls. While the kidneys typically manage phosphate balance through the reabsorption of the mineral via the NPT2A protein, the newly discovered TMEM174 acts as a necessary counterbalance. By binding to NPT2A, TMEM174 modulates the reabsorption rate, preventing the systemic accumulation of phosphate that triggers vascular damage.
Hyperphosphatemia is a common clinical challenge for patients with chronic kidney disease (CKD), as failing kidneys struggle to clear waste products from the bloodstream. The research found that while diet modification—specifically reducing processed foods containing phosphate additives—offers some benefit, maintaining strict phosphate control remains difficult for many patients.
Makoto Miyazaki, PhD, a research professor in the Division of Renal Diseases and Hypertension at the University of Colorado Anschutz School of Medicine, said that phosphate is really underestimated in terms of longevity in all mammals and that the higher the concentration of phosphate in the blood, the shorter the lifespan.
Miyazaki said that the deficiency of TMEM174 appears to be primarily genetic rather than a direct consequence of CKD progression. However, patients who possess this deficiency face a compounding risk when their renal function declines. Because phosphate is prevalent in a wide range of organic sources like meat and legumes, as well as common food additives, systemic management of phosphate levels remains a complex clinical standard of care.
The discovery of the TMEM174 pathway provides a new focal point for pharmacological intervention. Miyazaki said that the research team intends to further investigate the interaction between these kidney proteins and the hormones responsible for systemic chemical balance. For patients experiencing persistent vascular issues related to renal failure, these findings underscore the importance of ongoing monitoring by nephrologists and cardiovascular specialists.
Managing phosphate levels through clinical oversight is essential for patients with compromised kidney function. The research highlights that understanding these molecular mechanisms is a concrete step toward improving long-term health outcomes for individuals with phosphate imbalances.
“Scientists have been studying phosphate homeostasis for over 100 years, so to still find a new protein that regulates phosphate is kind of unique,” said Makoto Miyazaki.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.